ABSTRACT
INTRODUCTION
Current evidence suggests that most human genes exhibit alternative splicing (Kampa et al., 2004; Johnson et al., 2003) . Many aspects of splicing regulation are still unknown (Lareau et al., 2004) , but our knowledge is improving thanks to technology to measure expression of several exons or splice junctions per gene (Johnson et al., 2003; Le et al., 2004; Wang et al., 2003) . Such platforms can assess thousands of genes simultaneously, permitting large-scale analysis of alternative splicing. * To whom correspondence should be addressed.
With such platforms, the first analysis task tends to be identifying genes with different splicing in two or more different experimental conditions, such as treatment and control. Various methods have been developed, mostly following the intuition that splice variation can appear as a change in expression of one part of a gene versus another. Hu et al. (2001) approached this by identifying groups of probes that cluster spatially in the genome, with expression levels similar to each other but differing from the gene's average expression level. Johnson et al. (2003) estimated probe-level models of the expression data and applied a set of empirical thresholds to the residuals. Le et al. (2004) compared data from two different experimental conditions with data from a third set of experiments, obtained by mixing the two samples in equal portions. In this method, putative splice variation is recognized through anticorrelation in the expression levels of two different probe sets. Finally, Wang et al. (2003) applied prior knowledge of the transcripts expressed by the gene, identifying the relative concentration of each transcript that best explains the observed expression data.
We have developed a method called ANOSVA, ANalysis Of Splice VAriation. This method employs statistical testing principles to identify potential splice variation from expression data. The results can be assessed with standard confidence measures, without empirically derived thresholds. It requires no additional assays. In addition, it requires no prior transcript information, and thus can be applied when existing knowledge of the possible transcript isoforms is incomplete. When validated against spiked clone experiments, it yielded no false positives and few false negatives.
To illustrate potential applications of ANOSVA and related technology, we applied ANOSVA to data from a prototype mouse alternative splicing microarray, run on eight normal adult tissues: brain, heart, kidney, liver, lung, ovary, skeletal muscle and thymus. This yielded a set of genes with evidence suggesting tissue-specific splicing in normal tissue. In this set, we observed enrichment of several Gene Ontology (GO) processes (Gene Ontology Consortium, 2001) , suggesting that splice variation serves as a mechanism to modulate these processes between tissue types.
ANOSVA FRAMEWORK
Section 2.1 presents the intuition behind ANOSVA, and Section 2.2 presents the mathematical details. Section 2.3 outlines some limitations and presents usage guidelines.
Basic intuition
A basic probe-level model of oligonucleotide expression analysis, inspired by Li and Wong (2001) , states that for any probe i in any experiment j , the logarithm of the backgroundcorrected intensity (y ij ) is mostly a function of two factors. These are the concentration θ j of the target mRNA in the sample (target concentration) and a probe affinity term φ i relating changes in probe intensity to unit changes in target concentration.
When a gene produces only one splice form, this model works well. Since the target concentration is the same for every probe interrogating the gene, the differences in observed intensities result mostly from differences in probe affinities. Figure 1A illustrates this situation with two probe sets, P1 and P2, measured in two different experimental conditions, E1 and E2. Each experimental condition is assessed with a set of replicated experiments, with three experiments apiece. Two sources of variation can be observed. First, the overall expression level of this gene is higher in experiment set E1 than in E2; the leftmost heat map of Figure 1A shows that the E1 probe intensities are a lighter gray than the E2 intensities. Second, the probes in probe set P1 have lower affinities than those in P2, reporting lower intensities for the same target concentration. This is shown by the darker shades of gray in the left half of the left heat map. The model captures both sources of variation well: the estimated probe intensities resemble the actual intensities, and the residuals are uniformly close to zero. Now consider the case of multiple splice forms, shown in Figure 1B . The splice forms expressed in experiment set E2 hybridize to both probe sets, but those in E1 hybridize to P1 only. The model should have a separate concentration term for each splice form in each experiment for an effective performance (Wang et al., 2003) . If the model has only one concentration term per experiment, it cannot fit the observed data, as shown. The estimated data do not resemble the actual data, and the residuals are larger than in Figure 1A . Two other groups have observed that this breakdown in the singleconcentration model can suggest splice variation (Hu et al., 2001; Johnson et al., 2003) , with many of their predictions validated successfully by RT-PCR. Shown at the left is the observed log intensity of each probe in each experiment, with the probes grouped by probe set and the experiments grouped by experimental condition or experiment set. The estimated log intensities are shown in the center, and the residuals at the right. Note that when there is a change in splicing, the residuals form a pattern according to groups delineated by experiment set and probe set.
Notice that the residuals in Figure 1B form a pattern. All intensities in E1 and P2 were over-estimated, as shown by the negative (darker) residuals. At the sametime, all intensities in E1 and probe set P1 were under-estimated, yielding positive (lighter) residuals. The situation is reversed in E2, with negative residuals for P1 and positive residuals for P2. As a whole, the residual terms fall into groups, where all probes in one probe set and all experiments in one experiment set are a part of the same group. Within each group, the residuals follow a similar trend. Between groups, there can be contrasting trends. This grouping suggests that in some experiment set, some part of the gene is expressed disproportionately from the others, a potential indicator of alternative splicing.
Statistical modeling
Application of a classical ANOVA statistical model can be used to identify the sort of grouping in the residuals illustrated in Figure 1B . For one gene at a time, we shall take the log of all probe intensities observed in all experiments in a study, with each intensity term labeled by probe and experiment. We shall assume that each probe is associated with exactly one probe set, and each experiment is associated with exactly one set of replicated experiments or one experimental condition, and shall extend the labeling to include probe set and experiment set. We shall also assume that there are multiple probe sets per gene, potentially measuring different transcript features.
The ANOVA model fits the observed data to a linear model of one or more input quantities (factors), and can be used to estimate the importance of each factor to the model. For two-way ANOVA with replication, each observation y ij kl is modeled by a combination of two factors, as follows:
In an expression analysis framework, y ij kl represents the observed log intensity of probe k of probe set i, measured in experiment j of experiment set l. The two factors are probe set (indexed by i) and experiment set (indexed by j). The term µ is an intercept, and represents a baseline intensity level for all probes in all experiments. The term α i represents the linear contribution to y from probe set i, and in the language of the Li-Wong model is analogous to the average probe affinity φ i of each probe set. The term β j represents the linear contribution to y from the second factor and can be thought of as the average target concentration θ j for each experiment set. Notice the similarity between Equations 1 and 2. The differences are the addition of the terms µ and γ ij in Equation 2; and the fact that Equation 1 includes an affinity term for each probe and a concentration term for each experiment, whereas Equation 2 includes terms for the average affinity of each probe set and the average concentration of each replicate set. The term γ ij describes the interaction effect for each combination of the two factors. Statistically, an interaction effect represents information in the combination of the factors not represented by the factors independently. Stated more simply, it represents additional signal applied to every combination of the two factors to make the model fit the data. The ANOVA framework can be used to test the null hypothesis that the interaction terms are all zero as against the alternative hypothesis that one or more of the interaction terms is non-zero. Rejection of the null hypothesis indicates that it is unlikely the observed data are consistent with a model with no interaction terms. In expression analysis, rejection of this null indicates that the probe intensities cannot be modeled with one target concentration term per experiment and one affinity term per probe set. As described in Section 2.1, this suggests possible alternative splicing.
Note that the ANOVA interaction P -value describes the overall importance of interaction terms in modeling the expression data. Two different scenarios could yield an equally significant P -value. First, there could be one large interaction term, describing one specific combination of factors for which the single-concentration model does not fit well. This could be caused by one exon, measured by one probe set, with background-level expression in most experiments but high expression in one experiment set only. Second, a significant interaction P -value could result from the additive effects of several marginally significant interactions, each measuring a slight change from the expected expression level at each of several different probe sets. Note that the first case is more interesting in biological terms, because it suggests that splicing differs between experimental conditions to a greater degree.
We can identify such interactions by analyzing the significance of the interaction terms γ ij (Aiken and West, 1991) . For some probe set i in some experiment set j , if there is a large change in splicing then the coefficient γ ij would be large; if there is no major change of splicing, then the coefficient γ ij would be close to zero. We assess the significance of each interaction coefficient γ ij using a t-test, where the numerator is the coefficient (and is technically the difference between the coefficient and zero), the denominator is the standard error of the coefficient as derived in the linear modeling process. The number of degrees of freedom is N − v − 1, where N is the sample size and v, the number of terms in the statistical model.
To identify genes with significant splice variation, we assess the significance of each interaction coefficient γ ij for each probe set i and experiment set j . We record the smallest P -value, and interpret this P -value as a measure of confidence that the gene exhibits during alternative splicing.
Note that because we perform one t-test for each combination of probe set and experiment set, this method involves multiple comparisons, and the P -values should be interpreted accordingly. When the residuals are normally distributed, one can apply standard corrections, such as Bonferroni's correction. In our case, a preliminary analysis has suggested that the residuals are not distributed normally, and thus the standard correction methods are not applicable. Instead, we have corrected for multiple testing by choosing a somewhat more stringent P -value threshold.
We have focused on the task of identifying genes with significant evidence of splice variation. A related task is to identify specific alternative splicing events, such as the expression of an exon in only some experimental conditions. Although we have not explored this thoroughly, alternative splicing events could be recognized by this method by recording all significant P -values rather than recording only the most significant P -value. Another potential extension to this model concerns the fact that rather than using a specific probe affinity for each probe and specific concentration for each experiment, it uses an average probe affinity for each probe set and an average concentration for each experiment group. It is possible that an implementation with specific probe affinity and experimental concentration terms might improve the accuracy of this approach further. We have experimented with both types of models and have found the averages to be sufficient, as illustrated in Section 3.
Assumptions and limitations
Splice variation is one potential cause of significant interaction effects and cross-hybridization is another. If some probe set shows an elevated level of expression owing to crosshybridization with another gene, this method would falsely identify the first gene as an alternative splicing candidate. To guard against this, we excluded from analysis any probe that may hybridize to more than one target, according to genomic alignments of the probe sequences.
False positives could also be caused by probe sets that never record above-background expression or experiment sets in which the entire gene is not expressed. When a probe records no expression in some experiment, its intensity should be zero. Since ANOSVA requires log intensities, its intensity is set to a small number to avoid numerical exceptions. Thus, when a probe set is always absent, its estimated affinity term will be non-zero. Technically, this is an overestimate. If the rest of the gene is expressed highly in some experimental condition, then the concentration term will be large. When the probe intensities are estimated for this experiment set, the large concentration term will be added to the overestimated affinity term, and the intensities for all probes in this probe set will probably be overestimated. The model may compensate with a large negative interaction effect, generating a false positive. A similar situation occurs with experiment sets for which no probe set is present; at some probe set with high affinities, the estimated log intensities are the sum of a high probe affinity term and an overestimated concentration term, and thus may be overestimated. This pitfall can be avoided by filtering the input to ANOSVA, removing any probe set with no expression and any experiment set for which the gene is absent. Section 4 describes a method for the same.
Finally, there is a limit to the sensitivity: a point where genuine splice variation is not sufficient to yield any significant interaction effects. This limitation is best addressed by careful interpretation of the test results. Our null hypothesis H 0 -states that the relative abundance of the expressed splice forms is roughly the same in all experiment sets, or that the splicing of the gene does not change much. A failure to reject H 0 , does not mean that H 0 is true; it means that we do not have sufficient evidence to reject it with confidence.
Validation
We validated this method on a set of spiked clone experiments, using the mouse genes Dnase1 and Kzf1 and a prototype microarray described in Section 3. For each gene, we selected three commercially available clones, representing three distinct splice forms. In each of eight experiment sets (four experiments per set), each clone was spiked into a yeast complex background at the concentrations detailed in Table 1 and summarized as follows. Clone A was kept at a constant low concentration. The concentration of Clone B was increased progressively from low to moderate levels in both experiment sets 1-4 and 5-8. Clone C was absent in experiment sets 1-4 and was spiked at a high constant concentration in experiment sets 5-8.
For Dnase1, there were ten probe sets: one specific to Clone A, one specific to Clone B and the rest of the eight common to all clones. For Kzf1, there were seven probe sets: one specific to Clone A, two specific to Clone B, one specific to Clone C, one common to Clones A and B and two common to all clones. For each gene, we selected in turn each pair of probe sets, and tested for splice variation according to data from those two probe sets only. This yielded several tests with two genes, with straightforward analysis of the results. For each pair of probe sets, we determined if splice variation was expected by analyzing genomic alignments of the clone sequences and the probe sets Fig. 2 . For each pair of probe sets, we performed three tests with ANOSVA: one with experiment sets 1-8, one with experiment sets 1-4 and one with experiment sets 5-8. The first test reflects changes in the concentration for both Clones B and C, while the other tests reflect a changes in the concentration of Clone B only. We expected splice variation when the two probe sets hybridized to different clones, with two exceptions. When a probe set is common to all the clones and the other is We applied ANOSVA to data from each pair of probe sets, using experiment sets 1-8, 1-4 and 5-8. We determined when splice variation was expected according to genomic alignments of the clone sequences and the probe sets. True positives (TP) were cases where splice variation was expected and observed. True negatives (TN) were tests for which splice variation was not expected or observed. False positives (FP) were tests for which splice variation was observed but not expected, and false negatives (FN) were tests for which splice variation was expected but was not observed. FNs are shown in bold and there were no FPs. Table 2 for a description. a As described in Section 2.3, we did not use the probe set specific to Clone C in tests in which Clone C was always absent.
common to Clones A and B, we expected splice variation only if Clone C was present (experiment sets 1-8 or 5-8). When comparing a probe set specific to Clone A with the one specific to Clone C, we expected splice variation only when the concentration of Clone C was varied (experiment sets 1-8).
In all the tests, we applied ANOSVA with P < 0.01. Since the errors in the model, as outlined in Section 2.2, do not appear to be normally distributed, we do not interpret the P -value literally but rather treat it as a metric of confidence. Table 2 summarizes the results for Dnase1. For a total of 135 tests, 45 pairs of probe sets were tested with the three groups of experiment sets. Table 3 shows the results for Kzf1; 21 pairs of probe sets were tested in a total of 57 tests. In every case where splice variation was observed, it was expected. In most cases where splice variation was expected, it was observed. The exceptions are as follows.
There were false negatives on tests involving one probe set that hybridized to Clone B only and the one that hybridized Fig. 3 . This figure compares the intensities of the Kzf1 probe sets (1) specific to Clone B, (2) specific to Clone C and (3) common to all clones in experiment sets 5-8. The all-clone probe sets should show intensity levels increasing in parallel with those specific to Clone B, but do not. This is consistent with probe sets becoming saturated at high intensities. We observed a similar pattern with Dnase1.
to Clones A and B. Clone A was spiked at a constant low concentration, whereas the concentration of Clone B varied from a low to a medium level. Consequently, the target concentration of the second probe set exceeded that of the first marginally and was not detected by ANOSVA. This situation occurred when one probe set is specific to Clone B and the other one is common either to Clones A and B with Clone C being absent or to all clones.
We also observed false negatives in tests involving experiment sets 5-8, one probe set specific to either Clone A or Clone C and held at constant concentration, and one probe set common to all clones. The probe set common to all clones should record an expression level that starts high, and increases progressively in parallel with those of Clone B. However, as illustrated in Figure 3 , these probe sets record only a slight increase in expression. The target concentration of these probe sets is high, and their behavior is consistent with probe sets that are approaching saturation at high concentrations . In the test recorded as false negatives, we would expect splice variation because we would expect a moderate increase in expression at these probe sets. Instead, the probe sets recorded only a slight increase; when compared with a probe set at a constant concentration, the slight increase was beyond the sensitivity of this method.
MOUSE SPLICE VARIATION CHIP
We designed a custom oligonucleotide microarray (Fodor et al., 1991 (Fodor et al., , 1993 Pease et al., 1994) to monitor splice variation. All mouse cDNA sequences from the April 2002 releases of dbEST, RefSeq and Genbank were aligned to the mouse genome (April 2002, Whitehead). All alignments that met stringent reliability thresholds were retained for further analysis. These alignments were consolidated into a non-redundant set of splice variants using altMerge (Wheeler, 2002) . A total of 7197 genes showed evidence of multiple different splice variants and were selected for the array.
We designed probe sets for exonic regions selected according to three criteria, described as follows. For each exon that we classified as alternatively-spliced from the alignment data, we designed an exon probe set. When several exons were unique to one transcript, we designed a unique probe set for the regions distinct to the transcript, which might span multiple exons. For each gene, we designed one or more gene probe sets, the exons being common to all or most of the transcripts; this probe set might also span multiple exons. For each probe sets we selected up to 10 non-overlapping 25mer perfect match (PM) probes, according to performance estimates .
We designed a junction probe set for all splice junctions relating to an alternative splicing event, according to the alignment data. Each junction probe set was centered at the splice junction, and contained six overlapping 25mer PM probes spanning the splice junction, with offsets from the splice junction of −3, −2, −1, 1, 2 and 3 bases.
Altogether, the microarray contained 7637 exon probe sets, 6038 unique probe sets, 8388 gene probe sets and 40 940 junction probe sets for the 7197 genes.
REMOVING ABSENT FEATURES
ANOSVA is prone to false positives with probe sets that are always absent, and with experiment sets for which the gene is absent (as described in Section 2.3). This can be avoided by filtering such data from the input. The more familiar methods for estimating when a probe set is present in an experiment involve mismatch probes (Liu et al., 2002) , which were not available on this chip. Here, we outline the method we developed for this purpose. This method was applied the analysis of normal mouse tissues described in Section 5.
A probe's affinity is largely related to GC content of its probe sequence. If a probe sequence has high GC content, the probe will generally have a higher affinity and will record a higher intensity than AT-rich probes at the same target concentration .
In experiments with a related microarray, slightly less than half of the probe sets were present in normal mouse experiments according to MAS 5.0 (data not shown). Thus, we would expect roughly half of the probe sets to be present in similar experiments on normal mouse tissues. Thus, we would expect that if we selected all the probes on the chip with a specific GC content and ranked their intensities, the top half would be mostly from present probe sets, and the bottom would be mostly from absent probe sets.
For each experiment, we divided all probes into 26 GC content bins, from 0 (containing only As and Ts) to 25 (containing only Gs and Cs). Within each bin, we ranked all probes Fig. 4 . This figure compares our method for determining absent probe sets to MAS 5.0. This data was obtained using with mouse brain, run on a prototype array. The array contained both PM and MM probes, and probe sets interrogating 23 014 exons and 17 667 splice junctions. This method uses PM probes only, and was concordant with MAS 5.0 (which uses both PM and MM probes) with an area under the ROC curve of 0.77. according to increasing probe intensity. We normalized these rankings by dividing each rank position by the bin size, so that the highest-intensity probe for each bin had a rank of 1.0. These normalized rankings provide a rough estimate of the probability that the target of the probe was present in the experiment. We derived probe set-level probabilities from these probelevel probabilities using Fisher's method (Sokal and Rohlf, 1995) . A summary statistic X is computed from each probe i in the probe set as follows:
X was applied to the χ 2 -distribution with 2n degrees of freedom, where n is the probe set size. For each probe set, this yields a probability that its target was present in the experiment. We validated this method against MAS 5.0 using an array with 40 745 probe sets of PM and mismatch (MM) probes, but using the PM signal only. Using a set of 30 experiments, representing 10 types of adult mouse tissues, the results were concordant with MAS 5.0 present/absent calls; the percentage of probes predicted as present correlated with the percentage of probes observed as present with a correlation coefficient of 0.92. (See Fig. 4 ). We applied this method in Section 5 by withholding any probe set or experiment set for which the presence probability never exceeded an empirical threshold of 0.9.
IDENTIFYING PROCESSES ENRICHED FOR TISSUE-SPECIFIC SPLICING
To demonstrate application of ANOSVA and related microarray technology, we identified genes with possible tissue-specific splicing as follows. Eight mouse tissues were run against the microarray described in Section 3. They were all tissues from normal adult mice: brain, heart, kidney, liver, lung, ovary, skeletal muscle and thymus. Each tissue was run as a set of technical replicates with three assays per tissue sample and one tissue sample per tissue type. This chip contained no mismatch probes. On most Affymetrix chips, each PM probe is accompanied by a MM probe, with the MM intensity providing an estimate of nonspecific background hybridization. If no MM probe is present, another background correction method must be used. For each probe, we identified the lowest intensity and subtracted it from all other intensities of the same probe. This adjustment reduces the intensities of each probe by a constant amount. Although this will affect the terms in Equation 2 describing the overall intercept and the linear terms for average probe affinities, it does not affect the interaction terms. It might affect the standard error of the interaction coefficients, but this effect is likely to be small and avoided by using a slightly more conservative P -value cutoff. This process was also applied to the validation experiments in Section 2.4.
For each gene, we filtered out data from any probe set never present in any tissue, as described in Section 4. If there were at least two probe sets and two experiment sets remaining after filtering, we applied ANOSVA to test for splice variation. Of 7197 genes on the chip, ANOSVA could be applied to 4306. Out of 4306 genes, 2409 (56%) had a P -value below the cutoff of 0.01, suggesting potential tissue-specific splicing. This does not indicate the frequency of splice variation, as all genes on the chip were selected for prior evidence of splice variation. Furthermore, this analysis reflects variation between normal adult tissues only. We might observe additional alternative splicing events with a more diverse set of tissues.
We analyzed the list of 2409 genes with MAPPFinder in order to put this list into biological context (Doniger et al., 2003) . MAPPFinder compares two sets of genes, a positive set and a null model or background set, to identify portions of GO (Gene Ontology Consortium, 2001) with significant enrichment in the positive set. Our positive set consisted of genes with putative tissue-specific splicing. Our null model was all genes on the chip, each of which was selected for prior evidence of alternative splicing. Altogether, this relates multivariant genes with putative splice variation among normal tissues to a general set of multivariant genes, and suggests what types of processes are affected by tissue-specific splicing. Note that a process could be affected by tissue-specific splicing if only one gene exhibits splice variation, but the one gene represents a rate-limiting step. Nonetheless, if one sees When genes with significant evidence of tissue-dependent splicing in eight normal adult tissues are compared with all the genes on the chip, all of which were selected for prior evidence of alternative splicing, the following GO biological process terms show significant enrichment. 'Observed' indicates the number of genes with significant evidence of splice variation, and 'Expected' indicates the number that would be expected by random chance. Z is the Z-score computed by MAPPFinder, describing the difference between observed and expected, P describes the likelihood of observing this Z-score by random chance. a These two GO terms have the same Z-scores but different P -values. This results from the difference in the number of genes under each term, which in turn affects the likelihood that either term would receive as large a Z-score by random chance.
tissue-specific splicing in a substantial proportion of the genes in a process, then one can reasonably say that the entire process is affected by tissue-specific splicing. A common effect of splice variation is the removal of entire protein domains (Kriventseva et al., 2003) , often those involved in key interactions in an interaction network (Resch et al., 2004) . Therefore, if the gene products involved in a process tend to vary between tissues, the interaction network might also vary between processes. Thus, splice variation might provide a mechanism for tissue-dependent modulation of the process. There were GO terms assigned by MGD (Gene Ontology Consortium, 2001) for 1625 of 2409 genes in Set 1, and 4360 of 7197 genes in Set 2. Given the genes with GO mappings, MAPPFinder determines if each GO term shows significant enrichment in Set 1. For each GO term, the number of genes in each set mapping to the GO term are counted. We refer to these counts as N 1 and N 2 for Sets 1 and 2, respectively, and report N 1 as Observed in Table 4 . To estimate how many genes might map to the GO term by chance, N 2 is scaled by the ratio of the sizes of Sets 1 and 2. This is reported as Expected in Table 4 . Next, MAPPFinder computes a Z-score reflecting the degree of enrichment by dividing the difference between Observed and Expected by the standard deviation of Expected, as detailed elsewhere (Doniger et al., 2003) . Finally, it calculates a P -value from each Z-score by permuting the assignments between genes and GO terms, recalculating the Z-scores, and estimating how often the permuted data show a Z-score as large as the actual data. Permutation analysis reduces the effect of any false associations created by small sample size effects. If a GO term has been observed frequently in a small set of genes, its Z-score might be large but its P -value might not be significant. We selected GO terms for which P < 0.05 and Observed >2.
To limit redundancy, we filtered this list by assigning each GO term a weight of log 2 (Observed) * Z-score, and removing any node with a smaller weight than its parent. This yielded a list of general GO terms with significant enrichment, shown in Table 4 . If a GO term does not appear in this table, there are two explanations. First, the associated genes might not exhibit evidence of tissue-specific splicing frequently enough to yield a significant enrichment measure. Second, the process might involve genes with low expression levels, such that ANOSVA could not be applied to its data. If a GO term appears in Table 4 , it suggests that the gene products involved in these processes tend to vary in form from one tissue to another, suggesting in turn that the entire process might vary from one tissue to another.
Many of the processes shown in Table 4 are metabolic. In addition to the processes labeled with 'metabolism', there are other processes listed under metabolism in GO: energy pathways, electron transport and biosynthesis-related processes. These results are consistent with prior observations on enrichment of GO for multivariant genes (Liu and Altman, 2003; Zavolan et al., 2003) . To a lesser extent, Table 4 shows enrichment in processes related to signal transduction and cellular communication, such as transport. This result appears to contradict other results, which show such processes to be frequent in alternatively-spliced genes (Johnson et al., 2003) . There are two explanations. First, such genes tend to have a low expression, and might not have survived the input screening process. We tested this by applying MAPPFinder to the genes not scored; analysis of this set did, in fact, show enrichment in communication and signal transduction, as shown in the Supplementary data. Second, many genes involved in these processes exhibit alternative splicing, but there are also many such genes. Zavolan et al. (2003) reported that genes involved in signal transduction process exhibited evidence of splice variation as often as not. Similarly, we observed putative alternative splicing 199 signal transduction genes, roughly one-fourth of the signal transduction genes on the chip. Although this seems like a large number, the frequency was too low to constitute significant enrichment.
Finally, Table 4 shows significant enrichment in muscle development and muscle contraction. This appears to reflect that the tissue samples include heart and skeletal muscle, two different types of muscle. We verified this with a second analysis performed without these tissues. In this analysis, we observed a significant reduction in the Z-scores for both muscle contraction and muscle development.
The analysis data described in this section are available at https://bioinfo.affymetrix.com/Papers/ANOSVA/. This includes ANOSVA results for all genes that could be scored, MAPPFinder results for tissue-specific variation in all tissues and all non-muscle tissues, and MAPPFinder results on GO enrichment for the genes not scored by ANOSVA.
CONCLUSIONS
Alternative splicing is considered to be frequent and a major source of protein diversity (Lareau et al., 2004) . With the methods for measuring splice variation becoming easier, the estimation of its significance might increase further. This will underscore the need for appropriate analytical methods. We have developed a statistical method called ANOSVA to identify putative splice variation from expression data. The method is widely-applicable, requiring no data on the gene structure or expected transcript isoforms. When validated against spiked clone experiments, it produced no false positives and few false negatives. All false negatives involved slight changes in splice variation, reflecting limited sensitivity at the low end. Thus, when we do not detect splice variation, we should not assume that none occurred. As is true with many statistical methods, a failure to reject the null hypothesis does not indicate that the null hypothesis was true; it indicates that there was not sufficient evidence to reject it.
We demonstrated application of ANOSVA with an expression dataset derived from a prototype alternative splicing microarray and normal adult tissues. This yielded a set of genes with putative tissue-specific splicing. This set was enriched for metabolic processes, a result consistent with prior observations. This suggests that basic metabolic processes might differ between tissue types, with splice variation providing one component of the differentiation.
There are caveats with ANOSVA. It should be viewed as a predictive method only, since factors other than splice variation can yield the significant interaction effects that are key to the method. One factor is cross-hybridization. We avoided this by not using any probe that might hybridize to more than one target, an option that might not always be viable. Another is input data that include probe sets that are always at background, or experiment sets for which the entire gene is at background. We avoided this pitfall by removing data from any experiment set or probe set with no significant expression observed, and presented one method for identifying such data. Unfortunately, as illustrated in Section 5, we did not analyze many of the genes that are most interesting biologically: those involved in cell communication, signal transduction and transcription. This reiterates the importance of a classic problem in expression analysis: separating biological signal from background noise.
ANOSVA is designed to identify genes with putative splice variation. A related problem is to identify specific alternative splicing events. Although we have not explored this thoroughly, this problem could be addressed by recording all significant P -values rather than the most significant P -value only. If these splicing events were mapped to features of protein structure, such as domains, it might be feasible to assess transcript-level regulation of the portions of proteins with direct functional interpretations.
